NEOPALANA Proteomgenomic analysis

ABSTRACT: Neoadjuvant palbociclib and anastrozole (NeoPalAna) is a single-arm phase II clinical trial for patients with stage II/III ER+/HER2- breast cancer. Patients recieved Anastrozole for 4weeks followed by palbociclib. On day 15, patients were biopsied and Ki67% was determined. Patients with Ki67 >10% were deemed resistant to therapy. These biopsies were subsequently frozen for multi-omics processing

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Breast Cancer Cell

DISEASE(S): Breast Cancer

SUBMITTER: Matthew Holt  

LAB HEAD: Matthew V Holt

PROVIDER: PXD058250 | Pride | 2026-02-09

REPOSITORIES: Pride